Targeting melanocortin receptors as a novel strategy to control inflammation

Reference review by the Anna Catania and James M. Lipton group — pioneers in research on the anti-inflammatory actions of α-MSH, originally known only as a melanotropic hormone. Published in Pharmacological Reviews (one of the most cited journals in pharmacology), it consolidates decades of evidence on the role of the melanocortin system as an endogenous anti-inflammatory.

The review synthesizes preclinical and clinical data showing that α-MSH and its analogs modulate practically all forms of inflammation studied: fever, contact and allergic dermatitis, cutaneous vasculitis, fibrosis, ocular, gastrointestinal, brain and airway inflammation, and arthritis. The central proposed mechanism is inhibition of NF-κB nuclear translocation, resulting in coordinated reduction of adhesion molecules, inflammatory cytokines, chemokine receptors, T-cell proliferation and inflammatory cell migration.

The authors emphasize the preferential role of MC1R and MC3R receptors as targets for inflammatory control. MC1R is expressed on immune cells (macrophages, neutrophils, lymphocytes) and mediates direct anti-inflammatory effects at the inflammation site; MC3R in specific CNS and peripheral populations activates descending anti-inflammatory neural pathways. The authors discuss limitations of natural melanocortins (short half-life, lack of selectivity) and describe new selective agonists in development.

This article is cited over 1500 times and remains an obligatory reference for any discussion on clinical use or research in α-MSH and analogs with anti-inflammatory focus. It provided the pharmacological rationale that motivated the development of modern drugs such as bremelanotide (Vyleesi, MC4R) and setmelanotide (Imcivree, MC4R), and continues to inspire the search for selective MC1R/MC3R agents for psoriasis, rheumatoid arthritis and inflammatory bowel disease.